{"filings":[{"id":2577716,"accession_number":"0000879169-26-000058","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2026-08-31T20:29:25+00:00","items":["8.01"],"status":"ready","headline":"Incyte signs CMS Medicaid pricing deal for Jakafi, avoids GUARD/GLOBE mandates","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Agreement with CMS enables state Medicaid access to Jakafi and Jakafi XR at prices aligned with a group of advanced industrialized nations.","Company expects to be exempt from proposed CMS GUARD and GLOBE pricing models under the agreement.","Incyte states the deal will not affect its 2026 financial guidance or have a material impact on its future financial outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1895282,"accession_number":"0000879169-26-000053","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2026-07-28T11:02:34+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q2 revenue $1.67B (+38% YoY); raises FY2026 guidance; acquires Vega Therapeutics for $1.25B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net sales $1.49B (+40% YoY); GAAP diluted EPS $2.81, Non-GAAP diluted EPS $3.09.","Jakafi net sales $817M (+7%); Opzelura net sales $450M (incl. $246M one-time CMS benefit); ex-benefit $204M (+24%).","Raises FY2026 total net sales guidance to $5.13-5.26B from $4.77-4.94B; Opzelura guidance to $1.05-1.1B.","Completed acquisition of Vega Therapeutics for $1.25B upfront; adds latarcibart (Phase 3 VWD) to pipeline.","Hematology/Oncology net sales $222M (+69%); Niktimvo, Monjuvi/Minjuvi, Zynyz drive growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1471438,"accession_number":"0000879169-26-000048","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2026-07-06T20:06:20+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incyte completes $1.25B acquisition of Vega Therapeutics, adding Phase 3 VWD asset VGA039","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition adds VGA039, a novel monoclonal antibody in Phase 3 for von Willebrand disease (VWD).","Upfront payment of $1.25B; up to $750M in additional sales milestones for Star Therapeutics.","VGA039 has Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease FDA designations.","Transaction expected to be recorded as a one-time R&D expense in Q3 and full year 2026.","VGA039 is in pivotal Phase 3 VIVID-6 study; potential first once-monthly subcutaneous prophylactic for VWD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1176797,"accession_number":"0000879169-26-000046","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2026-06-22T11:00:40+00:00","items":["8.01"],"status":"ready","headline":"Incyte settles CMS dispute over Opzelura Medicaid rebates; records $246M benefit","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS will not apply line extension regulation to Opzelura as if it were a line extension of Jakafi; Incyte withdraws lawsuit.","One-time non-cash benefit of ~$246M in Q2 2026 from reversal of previously accrued liabilities through March 31, 2026.","No future accruals for potential line extension regulations; expects improvement to Opzelura's gross-to-net.","Company plans to update financial guidance on next scheduled earnings release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":945436,"accession_number":"0000879169-26-000043","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2026-06-09T20:06:50+00:00","items":["5.07"],"status":"ready","headline":"Incyte shareholders elect 8 directors, approve say-on-pay, ratify Ernst & Young at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 8 director nominees elected with overwhelming support; highest for Katherine High (172.3M for) and Edmund Harrigan (172.2M for).","Non-binding advisory vote on executive compensation approved: 145.9M for, 28.1M against.","Ratification of Ernst & Young as auditor for FY 2026 passed: 173.1M for, 12.5M against.","11.4M broker non-votes recorded on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":900159,"accession_number":"0000879169-26-000040","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2026-06-08T11:05:51+00:00","items":["8.01","9.01"],"status":"ready","headline":"Incyte to acquire Vega Therapeutics for $1.25B upfront; total up to $2.0B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquires Vega Therapeutics from Star Therapeutics; adds VGA039, a Phase 3 anti-Protein S mAb for von Willebrand disease.","Star receives $1.25B upfront; up to $750M in sales milestones for total consideration of $2.0B.","VGA039 has Breakthrough Therapy, Fast Track, and orphan drug designations from FDA; Phase 3 VIVID-6 trial ongoing.","Transaction approved by both boards; expected to close in Q3 2026 subject to HSR review.","Incyte expects a ~$1.25B R&D charge in Q3 and full year 2026 GAAP and non-GAAP results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99361,"accession_number":"0000879169-26-000023","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q1 revenue $1.27B (+21% YoY), Non-GAAP EPS $1.81 beats prior $1.16; pipeline expands","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net sales $1.10B (+20% YoY); Jakafi $758M (+7%), Opzelura $143M (+20%), Hem/Onc $204M (+116%).","GAAP net income $303M ($1.47 diluted EPS) vs $158M ($0.80) prior year; Non-GAAP diluted EPS $1.81.","Positive Phase 3 vitiligo results for povorcitinib; NDA accepted for HS; four product approvals/launches expected in next 12 months.","Appointed Suketu Upadhyay as CFO effective May 4, 2026; cash position $4.0B.","FY 2026 guidance reaffirmed: total net sales $4.77-$4.94B; R&D and SG&A expenses guided."],"consensus_eps_estimate":null,"consensus_eps_actual":1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":1272676000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115310,"accession_number":"0000879169-26-000018","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Incyte director Susanne Schaffert resigns from board effective April 15","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Susanne Schaffert notified Incyte of resignation from Board on March 26, 2026.","Resignation effective April 15, 2026; not due to any disagreement with the company.","Dr. Schaffert had served on the Board since 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115309,"accession_number":"0000879169-26-000016","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Incyte appoints Cagnoni as President, integrates U.S. commercial; Trotta departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pablo Cagnoni named President, Incyte and Global Head of R&D; replaces Bill Meury as President; Meury remains CEO.","Steven Stein promoted to EVP, Chief Medical Officer and Head of Late-stage Development.","Mohamed Issa becomes EVP and Head of U.S. Commercial; U.S. oncology and immunology teams integrated.","Matteo Trotta, EVP and GM of U.S. Dermatology, will leave Incyte after a transition period.","No changes to compensation for the impacted executives in connection with these title changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115308,"accession_number":"0000879169-26-000013","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA issues Complete Response Letter for Incyte's Zynyz in NSCLC due to facility inspection findings","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA CRL for Zynyz (retifanlimab) sBLA for metastatic NSCLC with platinum chemo, citing Catalent Indiana inspection findings.","CRL did not cite efficacy or safety concerns; Zynyz's data from Phase 3 POD1UM-304 trial remains positive.","Incyte working with FDA and Catalent Indiana to address CRL and support potential sBLA resubmission.","The inspection findings at Catalent Indiana (part of Novo Nordisk) are not specific to Zynyz.","No other approvability issues raised; drug substance manufacturer not a concern."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115307,"accession_number":"0000879169-26-000006","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q4 total revenue $1.51B (+28% YoY); FY 2025 net product revenue beat guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $1.51B (+28% YoY); net product revenue $1.22B (+20%). FY 2025 net product revenue $4.35B, above $4.23-4.32B guidance.","GAAP diluted EPS Q4 $1.46, FY $6.41; non-GAAP diluted EPS Q4 $1.80, FY $6.80.","2026 total net product revenue guidance $4.77-4.94B, including Jakafi $3.22-3.27B and Opzelura $750-790M.","Pipeline: positive frontMIND Phase 3 for tafasitamab in DLBCL; Jakafi XR filing submitted, decision mid-2026; INCA033989 registrational plans; ruxolitinib cream PN paused.","Cash $3.6B; entered option agreement with Prelude Therapeutics for JAK2V617F inhibitor program ($100M option exercise)."],"consensus_eps_estimate":null,"consensus_eps_actual":6.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":5141242000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131729,"accession_number":"0000879169-25-000122","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Incyte director Hervé Hoppenot retires from board effective Dec 10, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hervé Hoppenot retired from Incyte's Board of Directors effective December 10, 2025.","Hoppenot is the former Chairman and CEO of Incyte, serving as a director since 2014.","No replacement or additional board changes were announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131728,"accession_number":"0000879169-25-000115","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q3 revenue $1.37B (+20% YoY); raises FY 2025 product revenue guidance to $4.23-4.32B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $2.11 vs $0.54 YoY; Non-GAAP diluted EPS $2.26 vs $1.07.","Jakafi net revenue $791M (+7%), Opzelura $188M (+35%), Niktimvo $46M (launch).","Raised FY 2025 Jakafi guidance to $3.05-3.075B, other oncology to $550-575M.","FDA approved Opzelura for pediatric atopic dermatitis (age 2+).","Plan to start registrational program for INCA33890 in MSS CRC in 2026; paused INCA034460, INCB57643, povorcitinib in CSU."],"consensus_eps_estimate":null,"consensus_eps_actual":4.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":3634407000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131727,"accession_number":"0001104659-25-096632","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Incyte appoints Thomas Tray as principal financial officer effective Sept 16, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Tray, age 48, was appointed as principal financial officer, effective September 16, 2025.","Mr. Tray currently serves as VP, Finance and Chief Accounting Officer (principal accounting officer).","He joined Incyte in June 2005 as Manager, External Reporting and has held roles of increasing responsibility.","No arrangements or understandings existed for his appointment; no family relationships with directors or executive officers.","Mr. Tray holds a B.S. in Accounting from Mount Saint Mary's University and an Executive MBA from Saint Joseph's University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148303,"accession_number":"0000879169-25-000108","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Incyte CFO Christiana Stamoulis to step down effective September 16, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Christiana Stamoulis notified Incyte of her resignation to pursue another opportunity.","Departure effective September 16, 2025; she will remain to support transition.","Company has initiated process to appoint a successor CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148302,"accession_number":"0000879169-25-000100","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q2 2025 revenue up 16% to $1.216B; raised Jakafi and oncology guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $1.216B (+16% YoY); net product rev $1.059B (+17% YoY). GAAP EPS $2.04 diluted, vs $(2.04) loss a year ago.","Jakafi net rev $764M (+8%); full-year guidance raised to $3.0-3.05B (prev $2.95-3.0B). Opzelura $164M (+35%).","Niktimvo launch strong with Q2 rev $36M; other oncology guidance raised to $500-520M (prev $415-455M).","New CEO Bill Meury appointed June 26, 2025 upon retirement of Hervé Hoppenot.","Novartis royalty dispute settled; Jakafi royalty rate reduced by 50% starting Jan 1, 2025; $280M paid in settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":2.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":2268427000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167085,"accession_number":"0001104659-25-063675","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Incyte appoints William J. Meury as President and CEO; Hervé Hoppenot retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hervé Hoppenot retired as President & CEO effective June 26, 2025; will serve as special advisor for up to one year.","William J. Meury appointed President & CEO effective June 26, 2025; also joins the Board.","Meury receives base salary of $1.25M, target bonus 100%, and equity awards including sign-on PSUs with stock price hurdles.","Julian C. Baker, Lead Independent Director, assumes role of Chairman of the Board.","Board amends 2024 Inducement Stock Incentive Plan to increase authorized shares from 1M to 2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167084,"accession_number":"0000879169-25-000062","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Incyte shareholders approve 8.5M share increase in stock incentive plan, 1M in ESPP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stock incentive plan amendment approved: shares increased from 66.5M to 75.0M, plan extended 5 years.","ESPP amendment approved: shares reserved increased from 10.35M to 11.35M.","All 9 director nominees elected; advisory say-on-pay passed with 91% of votes cast.","Ernst & Young ratified as independent auditor for FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167083,"accession_number":"0000879169-25-000059","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Incyte settles JAKAFI royalty dispute with Novartis; pays $280M vs $537M accrued","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement resolves litigation over royalty duration under 2009 Collaboration and License Agreement.","Incyte to pay Novartis $280M; had $537.1M accrued as of March 31, 2025.","Royalty rate on future U.S. JAKAFI net sales reduced by 50% effective Jan 1, 2025.","Reduced royalty for Q1 2025 is ~$14.9M; $242.2M difference to be recorded in Q2 2025.","Settlement eliminates contingent liability and lowers future royalty expense."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167082,"accession_number":"0000879169-25-000053","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q1 2025 revenues up 20% to $1.05B; Jakafi guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $1,053M (+20% YoY); product rev $922M (+26%); GAAP diluted EPS $0.80; Non-GAAP $1.16.","Jakafi net product rev $709M (+24%); full-year 2025 guidance raised to $2,950-$3,000M.","Opzelura net rev $119M (+38%); Niktimvo launch rev $14M in first two months.","Povorcitinib meets primary endpoints in Phase 3 HS and Phase 2 CSU; supports regulatory submission.","Cash and marketable securities $2.4B; pipeline progress across MPN, oncology, and IAI programs."],"consensus_eps_estimate":null,"consensus_eps_actual":0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":1052898000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184450,"accession_number":"0001628280-25-004514","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q4 2024 revenue $1.18B (+16% YoY), guides 2025 Jakafi $2.93-2.98B, Opzelura $630-670M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenues $1.18B (+16% YoY); full year $4.24B (+15%). GAAP diluted EPS $1.02 (Q4), $0.15 (FY); Non-GAAP $1.43 (Q4), $1.08 (FY).","Jakafi net revs Q4 $773M (+11% YoY), FY $2.79B (+8%); Opzelura Q4 $162M (+48%), FY $508M (+50%).","FY2025 guidance: Jakafi $2,925-2,975M; Opzelura $630-670M; other oncology $415-455M.","Pipeline catalysts: Niktimvo launched; ruxolitinib XR bioequivalence met, submission by year-end 2025; four pivotal readouts in 2025.","Cash and securities $2.2B at Dec 31, 2024, down from $3.7B due to $2B share repurchase and $783M Escient acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":4241217000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184449,"accession_number":"0000879169-25-000011","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Incyte EVP North America Barry Flannelly retires; successor starts Jan 6","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Barry P. Flannelly, EVP General Manager North America, retired effective Jan 6, 2025.","He will remain employed through July 31, 2025 to assist with transition.","Successor commenced employment on Jan 6; name not disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201043,"accession_number":"0000879169-24-000169","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q3 2024 revenues up 24% to $1.14B; Jakafi guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $1.138B (+24% YoY); Jakafi net revenue $741M (+16%); Opzelura $139M (+52%).","GAAP diluted EPS $0.54 vs $0.76 YoY; Non-GAAP diluted EPS $1.07 vs $1.10.","Jakafi 2024 guidance raised to $2.74-2.77B; Other Heme/Onco guidance reduced to $310-320M.","FDA approved Niktimvo (axatilimab) for chronic GVHD; sNDA filed for ruxolitinib cream in pediatric AD.","Phase 3 retifanlimab in SCAC and tafasitamab in FL met endpoints; sBLAs planned by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":3062519000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217054,"accession_number":"0000879169-24-000146","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q2 net loss $445M; revs up 9% to $1.04B; Jakafi guidance raised; $2B buyback completed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $1,044M (+9% YoY); Jakafi $706M (+3%), Opzelura $122M (+52%).","GAAP net loss $444.6M vs $203.5M income in Q2 2023; non-GAAP net loss $396.1M.","Completed $2.0B share repurchase (33.3M shares at $60 each) in June 2024.","Raised low end of 2024 Jakafi revenue guidance to $2,710-$2,750M; revised R&D guidance up.","Discontinued development of oral PD-L1, LAG-3, TIM-3, LAG-3xPD-1; focus on high-impact programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":1924648000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217053,"accession_number":"0001104659-24-077770","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Incyte extends revolving credit facility maturity to June 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity of revolving credit facility extended from Aug 18, 2024 to June 28, 2027.","Amendment No. 2 entered on June 28, 2024; full agreement to be filed with Q2 2024 10-Q.","Incyte Holdings Corporation remains a guarantor; J.P. Morgan Chase is administrative agent.","No change to total commitment amount or other material terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236823,"accession_number":"0000879169-24-000082","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Incyte shareholders elect all 9 directors, approve executive compensation, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected with at least 171M votes for (89.6% to 99.4% of votes cast).","Non-binding advisory vote on named executive officer compensation approved: 171.7M for (89.6%).","Ratification of Ernst & Young as independent auditor approved: 186.6M for (92.3%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236822,"accession_number":"0001104659-24-060207","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Incyte commences $1.672B Dutch auction tender offer, agrees to buy $328M from Baker Entities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Incyte commences modified Dutch auction tender offer to repurchase up to $1.672 billion of common stock at $52-$60 per share.","Incyte enters stock purchase agreement with Baker Entities (own ~16.4% of shares) to buy up to $328 million at same price to maintain their ownership.","Total repurchase up to $2.0 billion, representing ~14.8%-17.1% of outstanding shares as of May 9, 2024.","Tender offer expires June 10, 2024; Baker Entities purchase expected 11 business days after offer completion.","Baker Entities include Julian C. Baker (board member) and entities advised by Baker Bros. Advisors LP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236821,"accession_number":"0000879169-24-000074","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q1 revenues $881M (+9% YoY), GAAP EPS $0.75; to acquire Escient for $750M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $881M (+9% YoY); GAAP net income $169.5M, diluted EPS $0.75.","Jakafi net revenues $572M (-1% YoY) despite 5% paid patient growth; inventory drawdown of ~$55M.","Opzelura revenues $86M (+52% YoY) driven by AD and vitiligo uptake.","Incyte to acquire Escient Pharmaceuticals for $750M plus net cash; lead candidate EP262 for CSU.","FY2024 guidance reaffirmed: Jakafi $2.69-2.75B; R&D $1.72-1.76B."],"consensus_eps_estimate":null,"consensus_eps_actual":0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":880889000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254429,"accession_number":"0000879169-24-000042","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte reports FY23 revenue $3.7B (+14%), Jakafi $2.59B, Opzelura $338M; guides 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total FY23 net product and royalty revenue $3.7B (+14% Y/Y); Q4 total revenue topped $1B for first time.","Jakafi FY23 net product revenue $2.59B (+8%); 2024 Jakafi guidance $2.69-$2.75B.","Opzelura FY23 net product revenue $338M (+162%) driven by atopic dermatitis and vitiligo launch.","GAAP FY23 net income $598M (diluted EPS $2.65); Non-GAAP net income $795M (diluted EPS $3.52).","Acquired worldwide rights to tafasitamab (Monjuvi/Minjuvi) from MorphoSys for $25M upfront."],"consensus_eps_estimate":null,"consensus_eps_actual":2.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":3695649000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271911,"accession_number":"0000879169-23-000038","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q3 2023 revenues up 12% to $919M; Jakafi guidance tightened to $2.59-2.62B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total GAAP revenues of $919M (+12% YoY); GAAP net income $171M ($0.76 diluted EPS).","Jakafi net product revs $636M (+3% YoY); Opzelura $92M (+141% YoY) on AD/vitiligo demand.","Non-GAAP diluted EPS $1.10 vs $0.60 in Q3 2022; operating income up 63% to $273M.","FY 2023 Jakafi guidance tightened to $2.59-2.62B from $2.58-2.63B; other guidance unchanged.","Phase 2 povorcitinib in prurigo nodularis met primary endpoint; Phase 3 planned for 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":1.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":2682308000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288758,"accession_number":"0001104659-23-100062","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Incyte EVP & General Counsel Maria Pasquale to retire Nov 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Maria E. Pasquale notified Incyte of her retirement effective November 1, 2023.","Her roles as EVP, General Counsel and Corporate Secretary may end earlier if successor is appointed.","Pasquale will remain employed through retirement date to assist with transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288757,"accession_number":"0000879169-23-000022","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q2 product revenue up 25% to $827M; raises Jakafi guidance; CSO departs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenue $827M (+25% YoY); Jakafi $682M (+14%), Opzelura $80M (+384%).","Raises Jakafi FY 2023 revenue guidance low end to $2.58-2.63B (from $2.55-2.63B).","Two pivotal trials met endpoints: ruxolitinib cream in pediatric AD (TRuE-AD3) and axatilimab in chronic GVHD (AGAVE-201).","CSO Dr. Dashyant Dhanak leaving effective Aug 2, 2023; oversaw 15+ IND filings during tenure."],"consensus_eps_estimate":null,"consensus_eps_actual":1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":1763283000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309416,"accession_number":"0001104659-23-071561","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Incyte shareholders approve 12.5M share increase in stock incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2010 Stock Incentive Plan, increasing shares by 12,500,000 to 66,453,475.","Stockholders approved amendment to 1997 Employee Stock Purchase Plan, increasing shares by 750,000 to 10,350,000.","All eight director nominees elected; say-on-pay approved with ~86.5% support; advisory vote set to every year.","Ratification of Ernst & Young as independent auditor for FY2023 approved with ~94.7% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309415,"accession_number":"0001104659-23-057267","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Incyte appoints Dr. Pablo J. Cagnoni as President, R&D, effective June 5, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board approved appointment of Pablo J. Cagnoni, M.D. as President, Research and Development on May 4, 2023.","Appointment becomes effective June 5, 2023.","No other executive changes or succession details disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309414,"accession_number":"0000879169-23-000014","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q1: Jakafi rev $580M (+7%); Opzelura $57M (+343%); raises Jakafi FY guidance to $2.55-2.63B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net product revenues $693M (+14% YoY); total GAAP revenues $808.7M (+10% YoY).","GAAP net income $21.7M ($0.10 diluted EPS) vs $38.0M ($0.17) in Q1 2022; Non-GAAP net income $84.6M ($0.37).","Jakafi FY 2023 guidance raised: bottom end to $2.55B from $2.53B; new range $2.55-$2.63B.","FDA issued complete response letter for ruxolitinib XR (once-daily) in MF, PV, GVHD; next steps unclear.","Discontinued parsaclisib combo trials in MF (LIMBER-304/313) and development in wAIHA; axatilimab Phase 2 cGVHD data on track for mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":808673000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328142,"accession_number":"0000879169-23-000005","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte reports FY2022 revenue $3.4B (+14%); Jakafi up 13%; provides 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 total revenues $3.39B (+14% YoY), net product rev $2.75B (+18%); GAAP diluted EPS $1.52, non-GAAP $2.78.","Jakafi net rev Q4 $647M (+9%), FY $2.41B (+13%); 2023 guidance range $2.53–2.63B.","Opzelura net rev Q4 $61M, FY $129M driven by atopic dermatitis and vitiligo launch; patent extended to 2040.","GAAP net income $341M (vs $949M in 2021, which included a large tax benefit); cash & securities $3.2B.","2023 guidance: Jakafi $2.53–2.63B; R&D $1.61–1.65B GAAP; SG&A $1.05–1.15B GAAP."],"consensus_eps_estimate":null,"consensus_eps_actual":1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":3394635000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345796,"accession_number":"0000879169-22-000007","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q3 product rev $713M (+20%); Jakafi guidance raised to $2.38-2.40B; Opzelura $38M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total product revenues $713M (+20% YoY); Jakafi $620M (+13%); Opzelura $38M ($0 prior year).","GAAP diluted EPS $0.50 (vs $0.82 YoY); Non-GAAP diluted EPS $0.60 (vs $1.18).","Jakafi FY22 guidance low end raised to $2.38-2.40B; other Hem/Onc rev guidance lowered to $200-210M on FX.","Pending acquisition of Villaris (auremolimab anti-IL-15Rβ mAb) for vitiligo; clinical start 2023.","Pipeline: once-daily ruxolitinib XR PDUFA Mar 23, 2023; axatilimab cGVHD results mid-2023; povorcitinib Ph3 HS end-2022."],"consensus_eps_estimate":null,"consensus_eps_actual":1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":2467935000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345795,"accession_number":"0001104659-22-105577","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2022-10-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Incyte elects Susanne Schaffert, former Novartis Oncology President, to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Oct 1, 2022, board increased to nine members, elected Susanne Schaffert.","Dr. Schaffert spent 26 years at Novartis, most recently President of Novartis Oncology (Jan 2019–Apr 2022).","She will serve as a non-employee director and receive standard cash/equity compensation.","No arrangement, family relationship, or reportable transaction exists with Dr. Schaffert.","She also serves on the board of Rubius Therapeutics, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362217,"accession_number":"0001558370-22-011546","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q2 total revenues up 29% to $911M; raises Jakafi guidance bottom end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $911M (+29% YoY); product revenues $664M (+15% YoY).","Jakafi net product revenues $598M (+13% YoY); FY guidance raised to $2.36-$2.40B.","GAAP diluted EPS $0.72; Non-GAAP diluted EPS $1.01 (up from $0.80 YoY).","Opzelura approved for vitiligo in July; ~48,000 units shipped in Q2 in atopic dermatitis launch.","Itacitinib development in chronic GVHD halted; pivotal trial deemed unlikely to succeed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":1644632000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381738,"accession_number":"0001104659-22-071867","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Incyte annual meeting results: all board nominees elected, Say-on-Pay and auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected; for votes ranged from 171.6M (Clancy) to 186.3M (Harrigan).","Say-on-Pay advisory vote approved with 170.6M for, 17.8M against, 82k abstain (90.5% of votes cast).","Ratification of Ernst & Young as auditor for FY2022 passed with 191.6M for, 8.4M against, 166.7k abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381737,"accession_number":"0001558370-22-006719","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q1 2022 revenue $733M (+21%); Jakafi guidance raised; Opzelura uptake strong","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total product & royalty revenues $728M (+20% YoY); GAAP net income $38M ($0.17 EPS); non-GAAP net income $123M ($0.55).","Jakafi net product rev $544M (+17% YoY); full-year guidance raised to $2.33-$2.40B from $2.3-$2.4B.","Opzelura >38,000 new patients in Q1; 146M lives covered; vitiligo sNDA under FDA review, PDUFA July 18.","Pemazyre approved in China; ruxolitinib QD NDA on track H1 2022; positive CHMP opinion for ruxolitinib in GVHD.","Cash, equivalents & securities $2.5B as of March 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":733235000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381736,"accession_number":"0001104659-22-048091","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2022-04-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Wendy L. Dixon to retire from Incyte board at 2022 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wendy L. Dixon notified Incyte on April 18, 2022, of her retirement.","Retirement effective at the Company's 2022 Annual Meeting of Stockholders.","Dr. Dixon served on the Incyte Board of Directors since 2010.","No replacement has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399721,"accession_number":"0001558370-22-000883","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2022-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q4 product/royalty rev $813M (+20%); non-GAAP EPS $0.10; 2022 Jakafi guidance $2.3-2.4B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Jakafi net product revenues $592M in Q4 (+15%) and $2.135B for FY21 (+10%).","GAAP net income $563.9M includes $569M tax benefit from valuation allowance release; non-GAAP diluted EPS $0.10.","Opzelura launch: ~19,000 patients treated in Q4; vitiligo sNDA under Priority Review with PDUFA April 18, 2022.","Parsaclisib NDA withdrawn for FL/MZL/MCL in U.S.; baricitinib SLE Phase 3 discontinued; baricitinib AD sNDA faces potential CRL.","2022 guidance: Jakafi $2.3-2.4B, other heme/onc $210-240M; GAAP R&D $1.55-1.59B, SG&A $950M-1B."],"consensus_eps_estimate":null,"consensus_eps_actual":4.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":2986267000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399720,"accession_number":"0001104659-22-004420","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2022-01-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Incyte names Thomas Tray as Principal Accounting Officer; Paul Trower to retire March 11, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Trower notified Incyte of retirement as Division VP, Finance and Principal Accounting Officer effective March 11, 2022.","Thomas Tray appointed VP, Finance and Chief Accounting Officer (Principal Accounting Officer) effective March 11, 2022.","Tray joined Incyte in 2005 as Manager, External Reporting, most recently served as VP and Controller.","Tray began his career at PricewaterhouseCoopers LLP and holds a B.S. in Accounting and an Executive MBA.","No arrangements or understandings existed regarding Tray's selection; no family relationships or material interests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418702,"accession_number":"0001558370-21-013984","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte Q3 GAAP net income $181.7M vs loss, revenue $812.9M (+31%); multiple approvals","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total product & royalty revenues $777.987M, +25% YoY; Jakafi $547.373M (+12%).","GAAP net income $181.739M ($0.82 diluted EPS) vs net loss $15.203M in Q3 2020.","Non-GAAP net income $261.824M ($1.18 diluted EPS) vs $50.059M.","FDA approved Opzelura for atopic dermatitis, Jakafi for chronic GVHD; Minjuvi OK'd in EU.","Reaffirmed FY2021 guidance: Jakafi net product rev $2,125-$2,170M; R&D $1,350-$1,390M GAAP."],"consensus_eps_estimate":null,"consensus_eps_actual":1.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":2123414000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418701,"accession_number":"0001104659-21-133095","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Incyte reports 3 product complaints for Opzelura cream; suspends affected batches","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Three product complaints received for Opzelura (ruxolitinib) cream related to texture.","FDA notified; root cause analysis underway; early testing shows no safety/efficacy issues.","Texture issue due to small amount of API not fully dissolved, causing slight gritty texture.","Distribution of affected batches suspended; no commercial supply issues at this time.","60g tubes that passed release and 90-day QC remain available; manufacturing continues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436294,"accession_number":"0001104659-21-120276","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2021-09-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Incyte elects Otis W. Brawley, M.D. to board effective Sept 27, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased to nine; Dr. Brawley elected as director effective September 27, 2021.","Dr. Brawley is Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.","Previously Chief Medical and Scientific Officer of American Cancer Society (2007–2018).","Will receive standard non-employee director compensation as described in 2021 proxy statement.","Dr. Brawley also serves on boards of Lyell Immunopharma and PDS Biotechnology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436293,"accession_number":"0001104659-21-108146","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2021-08-20T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Incyte enters $500M unsecured three-year revolving credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Facility of $500M with J.P. Morgan as admin agent; matures in three years.","Interest at base rate plus 0.125%-0.875% or Eurodollar rate plus 1.125%-1.875% based on leverage.","Commitment fee on undrawn amount from 0.150% to 0.225% per annum.","Financial covenant: maximum consolidated leverage ratio of 3.50 to 1.00.","Incyte Holdings guarantees; additional material domestic subsidiaries may become guarantors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436292,"accession_number":"0001558370-21-009865","cik":879169,"company_name":"INCYTE CORP","ticker":"INCY","form_type":"8-K","filed_at":"2021-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Incyte reports Q2 2021 product revenue $696M (+17% YoY); GAAP net income $149M vs $290M prior year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Jakafi net product revenues $529M (+12% YoY); total product and royalty revenues $696M (+17%).","Non-GAAP diluted EPS $0.80 vs $1.24 prior year; GAAP net income $149M down from $290M.","Positive CHMP opinion for tafasitamab in relapsed/refractory DLBCL; Phase 3 vitiligo trials met endpoints.","Updated 2021 guidance: Jakafi revenue tightened to $2,125-$2,170M; SG&A reduced to $725-$755M.","Retifanlimab BLA received FDA complete response letter; MAA still under EMA review."],"consensus_eps_estimate":null,"consensus_eps_actual":0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":1310427000.0,"consensus_period":"2020-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":19446794201.310402,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}